Takeda Pharmaceutical’s overseas sales ratio has reached 90.9%, exceeding 90% for the first time though only in the first half…
HOME > TOP STORIES
TOP STORIES
-
BUSINESS Some Drug Makers Rejuvenating Workforce by Boosting New Hires after Job Cuts: Jiho Survey
April 20, 2020
-
BUSINESS Big 3 Generic Makers to Discontinue Procaterol Tablets as API Procurement Stalls
April 17, 2020
-
BUSINESS Vibegron Prescription Soars after 14-Day Limit Lifted, Triggering Shipment Curbs
April 16, 2020
-
BUSINESS Gilead Japan to Seek Early Remdesivir Filing If Initial Data Prove Positive: Development Chief
April 16, 2020
-
BUSINESS Fujifilm Starts Boosting Avigan Production for COVID-19
April 16, 2020
-
BUSINESS Ono Curbing Camostat Supplies after Drug Reported as Potential COVID-19 Hopeful
April 15, 2020
-
BUSINESS Gilead Launches PIII Remdesivir Trials for COVID-19 in Japan
April 15, 2020
-
ORGANIZATION FPMAJ Ups Ante for Drug Supply Coordination amid COVID-19 Crisis
April 14, 2020
-
BUSINESS Tokushukai Preparing Model Formulary for 72 Group Hospitals; PPIs, Flu Drugs Eyed
April 14, 2020
-
REGULATORY Health Minister Vows to Shorten Review Time for Avigan
April 14, 2020
-
REGULATORY MSD’s 9-Valent HPV Vaccine Nearing Finish Line in Japan 5 Years after Filing, but Vaccination Policy Remains Iffy
April 13, 2020
-
BUSINESS After Valsartan, Towa Now Curbing Clindamycin Supplies as India Lockdown Continues
April 13, 2020
-
BUSINESS Chugai Shifting Resources to Beef Up Drug Discovery Prowess: New Chief
April 13, 2020
-
BUSINESS Sanofi Launches Kevzara Trial for Severe COVID-19 in Japan
April 10, 2020
-
BUSINESS Fujifilm to Start PII Avigan Trial for COVID-19 in US
April 10, 2020
-
BUSINESS Nichi-Iko Recalling 12 APIs/15 Products over Quality, Compliance Issues
April 9, 2020
-
REGULATORY Should Japan Go Ahead with Off-Year Re-Pricing amid COVID-19 Outbreak? Chuikyo Members Want It Discussed
April 9, 2020
-
BUSINESS Chugai to Launch Actemra PIII Trial for Coronavirus
April 9, 2020
-
REGULATORY Japan Books 13.9 Billion Yen to Boost Avigan Stockpile, Abe Vows to Expand Access to Fujifilm Drug
April 8, 2020
-
BUSINESS Rush to BCG Vaccine for COVID-19 Leads to Curbs on Shipments
April 7, 2020
ページ
In a recent conversation with James Feliciano, former president of AbbVie Japan, we delved into the intricacies of leadership in the Japanese pharmaceutical industry. Feliciano, a seasoned industry veteran, shared valuable insights into his experiences, challenges, and successes.Navigating the Abbott…
The Ministry of Health, Labor and Welfare (MHLW) on December 18 presented a proposal to define the scope of products…
Eli Lilly’s Kisunla (donanemab) will join the Japanese reimbursement list on November 20, with a health ministry panel giving the…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…